Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
作者信息
Choby Jacob E, Ozturk Tugba, Satola Sarah W, Jacob Jesse T, Weiss David S
机构信息
Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA.
Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA.
出版信息
Lancet Microbe. 2021 Dec;2(12):e648-e649. doi: 10.1016/S2666-5247(21)00271-8. Epub 2021 Oct 28.
Abstract
摘要
相似文献
1
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?头孢地尔异质性耐药能否解释 APEKS-NP 和 CREDIBLE-CR 临床试验结果之间的差异？
Lancet Microbe. 2021 Dec;2(12):e648-e649. doi: 10.1016/S2666-5247(21)00271-8. Epub 2021 Oct 28.
2
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.纳入前瞻性2期和3期随机临床研究的菌血症患者接受头孢地尔治疗的结果。
Infect Dis Ther. 2022 Apr;11(2):853-870. doi: 10.1007/s40121-022-00598-9. Epub 2022 Feb 20.
3
Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.头孢地尔对来自APEKS-NP和CREDIBLE-CR试验的含OXA-48分离株有效性的证据。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0110022. doi: 10.1128/aac.01100-22. Epub 2022 Sep 12.
4
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
5
Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.头孢地尔罗，一种针对多重耐药革兰氏阴性菌的新型抗生素。
Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):41-43. doi: 10.37201/req/s01.12.2021. Epub 2021 Sep 30.
6
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).美国食品药品监督管理局（FDA）：头孢地尔（Fetroja®）的获益-风险考量。
Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799.
7
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.头孢地尔罗：一种新型的用于治疗多重耐药革兰氏阴性菌感染的铁载体头孢菌素。
J Antimicrob Chemother. 2021 May 12;76(6):1379-1391. doi: 10.1093/jac/dkab015.
8
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.头孢地尔罗，一种新型的铁载体头孢菌素，用于治疗由多药耐药病原体引起的复杂性尿路感染：临床前和临床药代动力学、药效学、疗效和安全性。
Clin Drug Investig. 2020 Oct;40(10):901-913. doi: 10.1007/s40261-020-00955-x.
9
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
10
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.头孢地尔治疗医院获得性肺炎患者的血清铁水平和铁稳态参数：APEKS-NP 研究的事后分析。
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):467-476. doi: 10.1007/s10096-021-04399-9. Epub 2022 Jan 13.
引用本文的文献
1
Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline.拷贝数灵活性促进了对不断增加的抗生素压力的异质性耐药，并威胁到β-内酰胺类药物研发进程。
Nat Commun. 2025 Jul 1;16(1):5721. doi: 10.1038/s41467-025-60828-9.
2
The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review.治疗产金属β-内酰胺酶革兰氏阴性菌引起的感染面临的挑战：一篇叙述性综述
Drugs. 2024 Dec;84(12):1519-1539. doi: 10.1007/s40265-024-02102-8. Epub 2024 Oct 28.
3
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.碳青霉烯类耐药 株中阿维巴坦和舒巴坦与头孢地尔的异性拮抗作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.
4
Adaptive resistance to cefiderocol in carbapenem-resistant (CRAB): Microbiological and clinical issues.耐碳青霉烯类鲍曼不动杆菌（CRAB）对头孢地尔的适应性耐药：微生物学和临床问题
Heliyon. 2024 Apr 26;10(9):e30365. doi: 10.1016/j.heliyon.2024.e30365. eCollection 2024 May 15.
5
Heteroresistance to piperacillin/tazobactam in is mediated by increased copy number of multiple β-lactamase genes.多重β-内酰胺酶基因拷贝数增加介导了肺炎克雷伯菌对哌拉西林/他唑巴坦的异质性耐药。
JAC Antimicrob Resist. 2024 Apr 10;6(2):dlae057. doi: 10.1093/jacamr/dlae057. eCollection 2024 Apr.
6
Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Infections.头孢地尔治疗多重耐药感染的疗效和安全性的真实世界数据。
Open Forum Infect Dis. 2023 Dec 21;10(12):ofad627. doi: 10.1093/ofid/ofad627. eCollection 2023 Dec.
7
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant .头孢地尔和舒巴坦-度洛巴坦治疗耐碳青霉烯类感染
Antibiotics (Basel). 2023 Dec 14;12(12):1729. doi: 10.3390/antibiotics12121729.
8
Cephalosporin resistance, tolerance, and approaches to improve their activities.头孢菌素耐药性、耐受性及提高其活性的方法。
J Antibiot (Tokyo). 2024 Mar;77(3):135-146. doi: 10.1038/s41429-023-00687-y. Epub 2023 Dec 19.
9
An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.头孢地尔的治疗潜力及潜在耐药机制概述
Life (Basel). 2023 Jun 21;13(7):1427. doi: 10.3390/life13071427.
10
Induced Heteroresistance in Carbapenem-Resistant (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility.诱导耐碳青霉烯类抗生素鲍曼不动杆菌（CRAB）异质性耐药及其对头孢地尔洛敏感性的影响。
Int J Mol Sci. 2023 Jul 21;24(14):11752. doi: 10.3390/ijms241411752.
本文引用的文献
1
Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?治疗碳青霉烯类耐药鲍曼不动杆菌引起的严重感染患者：目前的选择有多大可行性？
Pharmacotherapy. 2021 Sep;41(9):762-780. doi: 10.1002/phar.2607. Epub 2021 Jul 22.
2
New Perspectives on Antimicrobial Agents: Cefiderocol.抗菌药物新视角：头孢地尔。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0217120. doi: 10.1128/AAC.02171-20.
3
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.碳青霉烯耐药革兰氏阴性病原体中广泛存在的头孢地尔异质性耐药。
Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8.
4
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).美国食品药品监督管理局（FDA）：头孢地尔（Fetroja®）的获益-风险考量。
Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799.
5
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
6
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
7
Cefiderocol: the Trojan horse has arrived but will Troy fall?头孢地尔：“特洛伊木马”已至，但特洛伊会沦陷吗？
Lancet Infect Dis. 2021 Feb;21(2):153-155. doi: 10.1016/S1473-3099(20)30828-8. Epub 2020 Oct 12.
8
Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?案例评论：头孢地尔的需求显而易见，但临床数据是否支持？
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00059-20.
9
Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection.抗生素组合利用对多种药物的异抗性可有效控制感染。
Nat Microbiol. 2019 Oct;4(10):1627-1635. doi: 10.1038/s41564-019-0480-z. Epub 2019 Jun 17.
10
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.2014 年至 2016 年全球范围内收集的碳青霉烯类药物不敏感和多重耐药革兰氏阴性杆菌的头孢菌素类抗生素头孢地尔的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
Zotero 插件